News

Filter

Current filters:

Merck KGaADiabetes

Merck Serono to partner with Lupin for emerging market exposure

Merck Serono to partner with Lupin for emerging market exposure

17-09-2014

Merck Serono, the biotech unit of Germany’s Merck KGaA, has entered a strategic partnership with Indian…

Antibiotics and Infectious diseasesBiotechnologyCardio-vascularDiabetesGermanyIndiaLicensingLupinMerck KGaAMerck Serono

Merck KGaA links with Bristol-Myers for Glucophage promotion in China

19-03-2013

German drugs and chemicals group Merck KGaA this morning announced a collaboration with US pharma major…

Asia-PacificBristol-Myers SquibbDiabetesGlucophageGlucophage XRLicensingMarkets & MarketingMerck KGaAPharmaceutical

Merck Serono collaborates with Neopharma for production in UAE

04-12-2012

Merck Serono, a division of Germany's Merck KGaA (MRK: DE), Germany, and Unite Arab Emirates drug manufacturer…

DiabetesEuthyroxGlucophageGlucophage XRMerck KGaAMerck SeronoNeopharmaPharmaceuticalProductionRest of the WorldWomen's Health

Galapagos expands metabolic disease with Merck & Co; will now get more than 400 million euros

15-10-2009

Belgian firm Galapagos has expanded its global strategic alliance in metabolic diseases with an affiliate…

Cardio-vascularDiabetesEuropeLicensingMerck KGaAMetabolicsNorth AmericaPharmaceutical

AstraZeneca’s potential blockbuster diabetes drug Onglyza approved by EC

06-10-2009

The European Commission has granted marketing authorization for Anglo-Swedish drug major AstraZeneca…

AstraZenecaBristol-Myers SquibbDiabetesEuropeJanuviaMerck KGaANystatinOralPharmaceuticalsitagliptin

Back to top